IonQ Trading Volume Drops 30% to $622 Million Ranking 132nd in Stock Market

Generated by AI AgentAinvest Volume Radar
Friday, Jun 27, 2025 8:01 pm ET1min read

On June 27, 2025, IonQ's trading volume reached $622 million, a 30.03% decrease from the previous day, ranking 132nd in the day's stock market. IonQ's stock price fell by 2.19%.

IonQ is aiming to scale physical qubits from the current hundreds to 2 million by 2030, with logical error rates so low that they would rival classical computers. This ambitious goal underscores the company's commitment to advancing

technology.

IonQ's trapped-ion architecture has achieved impressive single-qubit gate error rates of 0.05% and two-qubit gate error rates of 0.4%, enabling its 21-qubit Aria system to perform complex computations with high accuracy. This technological breakthrough positions

as a leader in the quantum computing industry.

IonQ has demonstrated its commercial traction by offering quantum computing as a service through major cloud providers. This approach allows the company to sidestep the capital-intensive challenge of selling hardware while capturing market share in the growing quantum computing sector.

In 2024, IonQ and

collaborated on a quantum-assisted chemistry simulation for a drug discovery process, achieving a 20× speedup in a key step. This collaboration highlights the practical applications of quantum computing in various industries, including pharmaceuticals.

IonQ and the University of Washington have performed the first known quantum simulation of “neutrinoless double-beta decay” on IonQ's Forte Enterprise system. This groundbreaking achievement further solidifies IonQ's position as a pioneer in quantum computing research and development.

IonQ has announced an agreement to acquire Oxford Ionics, accelerating its path to pioneering breakthroughs in quantum computing. This strategic acquisition is expected to enhance IonQ's technological capabilities and market leadership in the quantum computing industry.

Comments



Add a public comment...
No comments

No comments yet